News | Proton Therapy | February 16, 2016

Mevion S250 Proton Therapy System Comes to Nation's Capital

Mevion proton accelerator arrives at Medstar Georgetown; one of multiple Mevion sites to achieve installation milestones

Mevion S250, proton therapy, Medstar Georgetown installation, Washington D.C.

February 16, 2016 – A superconducting synchrocyclotron proton accelerator was delivered Valentine’s Day weekend to MedStar Georgetown University Hospital. The accelerator, which will become the core of the hospital’s Mevion S250 proton therapy system, was developed and manufactured in the United States and is one of only eight in existence.

When installation is complete, cancer patients in the Washington, D.C. area will gain access to proton therapy — an advanced form of radiation treatment that targets tumors precisely, while sparing much of the surrounding healthy tissue. Because of its accuracy, proton therapy is ideal for treating pediatric patients, as well as adults with cancers in or near sensitive locations, such as the heart, lungs, brain, eye or spinal cord.

Conventional proton therapy systems can cost over $200 million to construct and are typically the size of a football field. The Mevion S250 delivers proton therapy for up to 80 percent less cost and 90 percent less space. Mevion systems also require up to 75 percent fewer staff and use up to 90 percent less energy than other proton systems. Furthermore, Mevion says its proton systems have an industry leading ramp-up time, throughput capabilities and uptime.

Installation of the system at MedStar Georgetown will take approximately 10 months. The system will then undergo proton beam tuning to meet the precise clinical requirements for patient treatments. The first proton therapy patient is expected to be treated at MedStar Georgetown in early 2017.

The Washington, D.C. installation begins as Ackerman Cancer Center (ACC) in Jacksonville, Fla., breaks ground on the construction of a radiation vault for its second Mevion S250 Series system. ACC will be installing a Mevion S250i with Hyperscan pencil beam scanning technology.

The first system opened last April, and quickly achieved the fastest per-room ramp-up in the history of proton therapy. The installation is expected to be completed in 2017.

Meanwhile, the Mevion S250 under installation at the University of Florida (UF) Health Cancer Center – Orlando Health, in Orlando, Fla., has also achieved a major milestone. It has completed its rigorous acceptance testing and is now entering the clinical commissioning phase. Clinical commissioning is the final step before the first patient is treated.

During an intensive seven days of acceptance testing, the system in Orlando met or exceeded all specifications. Its operational control has been officially transitioned to the physics and radiation oncology proton teams at UF Health Cancer Center. It is expected to begin treating patients in a few months.

For more information: www.mevion.com

Related Content

Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at th
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...